This research study aims to compare the impact of short-term (<12 months) and long-term (>12 months) calcitonin gene-related peptide (CGRP) antagonist use on migraine-related quality of life, disability, and migraine symptoms.
What is this research study about?
This research study aims to compare the impact of short-term (<12 months) and long-term (>12 months) calcitonin gene-related peptide (CGRP) antagonist use on migraine-related quality of life, disability, and migraine symptoms.
You may be eligible for this study if you:
• Aged 18 years and over,
• Have been diagnosed with chronic migraine and,
• Are currently using a CGRP antagonist
What is required of me?
You will be required to complete a short (approximately 20-minute) online survey.
When is enrolment for study closing?
Enrolment for the study closes January 31, 2024.
For further information and to register for the study, please contact Miss Myah Passmore ([email protected]) OR scan the
QR code.
This project has been approved by Griffith University Human Research Ethics Committee | GU Ref No: 2023/793
Project Investigators:
Dr Henry Ndukwe
Dr Jemima Dzator
Miss Myah Passmore
"Please be aware of the potential dangers of accidental public exposure when commenting and interacting with this post. Please be mindful of maintaining your privacy and the privacy of others."